XM无法为美国居民提供服务。

XM无法为美国居民提供服务。
R
R

Regeneron

市场新闻

Reuters - 3小时前

What to Watch in the Week Ahead and on Monday, October 28

What to Watch in the Week Ahead and on Monday, October 28 The Day Ahead is an email and PDF publication that includes the day's major stories and events, analyses and other features. To receive The Day Ahead, Eikon users can register at DAY/US . Thomson One users can register at RT/DAY/US. All times in ET/GMT ON MONDAY Ford is expected to report higher third-quarter revenue and profit, aided by sales of its commercial vehicles.
A
A
B
C
C
C
C
D
G
I
J
M
P
P
R
S
K
K
E
R
U
Reuters - 2天前

U.S. Coca-Cola, Nextera Energy Partners, ServiceNow

U.S. RESEARCH ROUNDUP-Coca-Cola, Nextera Energy Partners, ServiceNow Oct 24 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies including Coca-Cola, Nextera Energy Partners, and ServiceNow on Thursday. HIGHLIGHTS * Avery Dennison Corp AVY.N : JP Morgan cuts to neutral from overweight * Coca-Cola Co KO.N : JP Morgan cuts target price to $75 from $78 * Nextera Energy Partners LP NEP.N : JP Morgan raises to neutral from underweight *
A
A
A
B
C
D
D
E
E
N
R
C
L
T
E
E
I
S
T
A
A
E
E
G
H
L
R
Reuters - 3天前

Regeneron loses bid to block Amgen's Eylea biosimilar launch in US

UPDATE 1-Regeneron loses bid to block Amgen's Eylea biosimilar launch in US Adds comments from Regeneron and Amgen in paragraphs 3-4, additional context in paragraphs 5-8 By Blake Brittain Oct 22 (Reuters) - Amgen AMGN.O will launch its biosimilar version of Regeneron's REGN.O blockbuster eye care drug Eylea following a U.S. appeals court ruling in its favor on Tuesday, an Amgen spokesperson said.
A
R
Reuters - 3天前

Amgen to launch US Eylea biosimilar after ruling in Regeneron patent case

Amgen to launch US Eylea biosimilar after ruling in Regeneron patent case By Blake Brittain Oct 22 (Reuters) - Amgen AMGN.O will launch its biosimilar version of Regeneron's REGN.O blockbuster eye care drug Eylea following a U.S. appeals court ruling in its favor on Tuesday, an Amgen spokesperson said. The U.S. Court of Appeals for the Federal Circuit rejected Regeneron's request to temporarily block the launch during its appeal of a related decision for Amgen in a patent case in West Virginia.
A
R
Reuters - 1周前

Three-Year Results For Eylea Hd (Aflibercept) Injection 8 Mg Demonstrate Continued Durable Vision Gains And Anatomic Improvements With Extended Dosing Intervals In Patients With Diabetic Macular Edema

BRIEF-Three-Year Results For Eylea Hd (Aflibercept) Injection 8 Mg Demonstrate Continued Durable Vision Gains And Anatomic Improvements With Extended Dosing Intervals In Patients With Diabetic Macular Edema Oct 18 (Reuters) - Regeneron Pharmaceuticals Inc REGN.O : THREE-YEAR RESULTS FOR EYLEA HD® (AFLIBERCEPT) INJECTION 8 MG DEMONSTRATE CONTINUED
R
Reuters - 2周前

Amgen falls as Truist downgrades to 'hold' on competition for experimental skin disease drug

BUZZ-Amgen falls as Truist downgrades to 'hold' on competition for experimental skin disease drug ** Shares of drugmaker Amgen AMGN.O fall 1% to $324.95 ** Truist Securities downgrades stock to "hold" from "buy", citing "extremely competitive" landscape for an experimental drug to treat atopic dermatitis or eczema ** Brokerage also raises PT to $33
A
R
S
Reuters - 2周前

Teva to pay $450 million to resolve US kickback, price-fixing cases

UPDATE 1-Teva to pay $450 million to resolve US kickback, price-fixing cases Adds details on settlement, background of case throughout By Nate Raymond BOSTON, Oct 10 (Reuters) - Teva Pharmaceutical Industries Ltd TEVA.TA has agreed to pay $450 million to resolve allegations it used charities that help cover Medicare patients' out-of-pocket drug costs as a means to pay kickbacks to boost sales of its multiple sclerosis drug Copaxone and conspired to fix prices for generic drugs.
R
T
Reuters - 2周前

Clearside jumps as eye disease drug succeeds in mid-stage trial

BUZZ-Clearside jumps as eye disease drug succeeds in mid-stage trial ** Shares of drug developer Clearside Biomedical CLSD.O rise ~38.5% to $2.05 premarket ** Company says its drug CLS-AX showed stable vision in patients with wet age-related macular degeneration for up to 6 months compared to Regeneron Pharmaceuticals' REGN.O aflibercept, during a
R
Reuters - 3周前

Regeneron Pharmaceuticals Says Acquired IPR&D Charge Expected To Negatively Impact Q3 Adjusted EPS By About $0.43

BRIEF-Regeneron Pharmaceuticals Says Acquired IPR&D Charge Expected To Negatively Impact Q3 Adjusted EPS By About $0.43 Oct 7 (Reuters) - Regeneron Pharmaceuticals Inc REGN.O : REGENERON PHARMACEUTICALS - EXPECTS Q3 RESULTS WILL INCLUDE ACQUIRED IPR&D CHARGE OF ABOUT $56 MILLION ON PRE-TAX BASIS REGENERON PHARMACEUTICALS INC - ACQUIRED IPR&D CHARGE
R
Reuters - 3周前

Regeneron loses key defense in 19 treatment patent lawsuit

Regeneron loses key defense in COVID-19 treatment patent lawsuit By Blake Brittain Oct 4 - Biotech company Regeneron Pharmaceuticals REGN.O lost a bid on Friday to be held immune from allegations that it misused a patented protein while testing a COVID-19 treatment. U.S. District Judge Philip Halpern rejected Regeneron's pretrial argument that he should throw out Allele Biotechnology and Pharmaceuticals' patent lawsuit over the treatment based on a federal law allowing the use of patented invent
P
R
Reuters - 3周前

Nasdaq top and bottom performing stocks at about 03:45 p.m. EDT

BUZZ - Nasdaq top and bottom performing stocks at about 03:45 p.m. EDT Nasdaq 100 .NDX Top Performers Percent Change Constellation Energy Corp CEG.OQ +3.9% Diamondback Energy Inc FANG.OQ +3.7% NVIDIA Corp NVDA.OQ +3.0% Paccar Inc PCAR.OQ +2.8% Trade Desk Inc TTD.OQ +2.2% Bottom Performers Percent Change Tesla Inc TSLA.OQ -3.9% Warner Bros Discovery Inc WBD.OQ -3.5% Take-Two Interactive Software Inc TTWO.OQ -2.9% Moderna Inc MRNA.OQ -2.8% Regeneron Pharmaceuticals Inc REGN.OQ -2.8% The Nasdaq 100
N
P
R
T
T
U
D
T
Reuters - 4周前

U.S. stocks weekly: Streaking in September

RPT-BUZZ-U.S. stocks weekly: Streaking in September Repeats from Friday with no changes to text. Updates chart ** S&P 500 .SPX extends winning streak to three weeks, adds 0.6% amid tame inflation data and China stimulus boost .N ** SPX on pace for monthly gain, take that September! ** Dow .DJI and Nasdaq .IXIC also up three consecutive weeks, though the latter still lined up at the velvet rope ** This as benchmark Treasury yield perks up , but can't hold 3-week highs after PCE ** Most sectors fl
A
C
M
R
V
L
W
U
U
Reuters - 4周前

U.S. stocks weekly: Streaking in September

BUZZ-U.S. stocks weekly: Streaking in September ** S&P 500 .SPX extends winning streak to three weeks, adds 0.6% amid tame inflation data and China stimulus boost .N ** SPX on pace for monthly gain, take that September! ** Dow .DJI and Nasdaq .IXIC also up three consecutive weeks, though the latter still lined up at the velvet rope ** This as benchmark Treasury yield perks up , but can't hold 3-week highs after PCE ** Most sectors fleet of foot: Materials sprint to front of the pack, while Energ
A
C
M
R
V
L
W
U
U
Reuters - 4周前

U.S. STOCKS IonQ, Cassava Sciences, MeridianLink

BUZZ-U.S. STOCKS ON THE MOVE-IonQ, Cassava Sciences, MeridianLink Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 The blue-chip Dow rose on Friday to hit an intraday record and small-cap stocks outperformed after a benign inflation report cleared the way for the Federal Reserve to focus on shoring up the labor market while continuing its interest rate easing.
C
E
R
S
R
W
U
U
G
C
L
Reuters - 4周前

U.S. STOCKS Regeneron, HP Inc, Honeywell International

BUZZ-U.S. STOCKS ON THE MOVE-Regeneron, HP Inc, Honeywell International Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 The blue-chip Dow rose on Friday to hit an intraday record high and small-cap stocks outperformed after a benign inflation report cleared the way for the Federal Reserve to focus on shoring up the labor market while continuing its interest rate easing.
A
C
E
L
R
S
W
W
U
U
D
C
L
Reuters - 4周前

Regeneron rises as US FDA approves Dupixent for 'smoker's lung'

BUZZ-Regeneron rises as US FDA approves Dupixent for 'smoker's lung' ** Shares of Regeneron Pharmaceuticals REGN.O rise 1.6% to $1,056.92 in early trading ** Co and French partner Sanofi SASY.PA say the U.S. FDA has approved their blockbuster drug, Dupixent, for patients with a chronic lung disease commonly known as "smoker's lung" ** Dupixent is t
R
S
Reuters - 4周前

Sanofi-Regeneron's Dupixent wins FDA's nod for 'smoker's lung'

UPDATE 2-Sanofi-Regeneron's Dupixent wins FDA's nod for 'smoker's lung' Adds details on Dupixent in paragraphs 2 and 4, analyst estimates in paragraph 5, trial details in paragraph 8 By Sriparna Roy Sept 27 (Reuters) - The U.S. Food and Drug Administration has approved Sanofi SASY.PA and Regeneron's REGN.O blockbuster drug Dupixent for patients with a chronic lung disease, commonly known as "smoker's lung", the companies said on Friday.
R
S
Reuters - 4周前

Dupixent approved in United States as first-ever biologic medicine for patients with COPD

BRIEF-Dupixent approved in United States as first-ever biologic medicine for patients with COPD Sept 27 (Reuters) - Sanofi SA SASY.PA /REGENERON REGN.O : PRESS RELEASE: DUPIXENT APPROVED IN THE US AS THE FIRST-EVER BIOLOGIC MEDICINE FOR PATIENTS WITH COPD PRESS RELEASE: DUPIXENT APPROVED IN THE US AS THE FIRST-EVER BIOLOGIC MEDICINE FOR PATIENTS WI
R
S
Reuters - 4周前

US FDA approves Sanofi-Regeneron's Dupixent for 'smoker's lung'

US FDA approves Sanofi-Regeneron's Dupixent for 'smoker's lung' Sept 27 (Reuters) - The U.S. Food and Drug Administration has approved Sanofi SASY.PA and Regeneron's REGN.O blockbuster drug Dupixent for patients with a chronic lung disease commonly known as "smoker's lung", the companies said on Friday. Reporting by Sriparna Roy in Bengaluru; Editi
R
S
Reuters - 4周前

What to Watch in the Day Ahead - Friday, September 27

What to Watch in the Day Ahead - Friday, September 27 The Day Ahead is an email and PDF publication that includes the day's major stories and events, analyses and other features. To receive The Day Ahead, Eikon users can register at DAY/US . Thomson One users can register at RT/DAY/US. All times in ET/GMT Federal Reserve Board Governor Michelle Bowman is set to participate in a conversation before the Alabama Bankers Association Bank CEO Meeting in Birmingham, Alabama.
B
R
S

商品详情

热门商品

免责声明: XM Group仅提供在线交易平台的执行服务和访问权限，并允许个人查看和/或使用网站或网站所提供的内容，但无意进行任何更改或扩展，也不会更改或扩展其服务和访问权限。所有访问和使用权限，将受下列条款与条例约束：(i) 条款与条例；(ii) 风险提示；以及(iii) 完整免责声明。请注意，网站所提供的所有讯息，仅限一般资讯用途。此外，XM所有在线交易平台的内容并不构成，也不能被用于任何未经授权的金融市场交易邀约和/或邀请。金融市场交易对于您的投资资本含有重大风险。

所有在线交易平台所发布的资料，仅适用于教育/资讯类用途，不包含也不应被视为用于金融、投资税或交易相关咨询和建议，或是交易价格纪录，或是任何金融商品或非应邀途径的金融相关优惠的交易邀约或邀请。

本网站上由XM和第三方供应商所提供的所有内容，包括意见、新闻、研究、分析、价格、其他资讯和第三方网站链接，皆保持不变，并作为一般市场评论所提供，而非投资性建议。所有在线交易平台所发布的资料，仅适用于教育/资讯类用途，不包含也不应被视为适用于金融、投资税或交易相关咨询和建议，或是交易价格纪录，或是任何金融商品或非应邀途径的金融相关优惠的交易邀约或邀请。请确保您已阅读并完全理解，XM非独立投资研究提示和风险提示相关资讯，更多详情请点击 这里。

风险提示： 您的资金存在风险。杠杆商品并不适合所有客户。请详细阅读我们的风险声明。